U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07409259) titled 'PT-MSCs Exosome Injection in the Treatment of Chronic-to-acute Liver Failure' on Jan. 12.
Brief Summary: The goal of this single-center, prospective, randomized controlled study is to evaluate the safety and efficacy of PT-MSCs Exosome Injection (code: PT-MSCs-EVS-2023-1) in treating patients with acute-on-chronic liver failure (ACLF). As an exploratory study with a small sample size, the primary focus is to observe safety outcomes and preliminary efficacy. The study will enroll patients aged 18 to 65 years who meet the diagnostic criteria for acute-on-chronic liver failure as outlined in the 2024 Chinese Liver Failure Clinical Guid...